BLOOMIOS, INC.

CIK:0001138608|SEC Filings

Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Consolidated Statement of Operations (Unaudited)
Sales	$ 682,036	$ 1,197,927	$ 6,110,251	$ 3,957,356
Cost of Goods Sold	366,294	597,621	4,294,144	1,967,220
Gross Profit	315,742	600,306	1,816,107	1,990,136
General and Administrative	163,647	255,456	1,058,297	919,503
Salaries	339,098	647,073	2,129,753	1,890,090
Rent	108,540	105,438	715,106	310,422
Utilities	0	40,002	63,924	106,467
Professional fees	49,750	30,751	184,157	141,012
Consulting	157,694	229,500	768,968	739,424
Depreciation	42,043	109,275	126,129	322,308
Share based Expense	95,218	95,217	439,154	285,901
Total Expenses	955,990	1,512,712	5,485,488	4,715,127
Net Profit From Operations	(640,248)	(912,406)	(3,669,381)	(2,724,991)
Other Income / (Expenses)
Shares issued for inducement	(148,485)	(510,620)	(148,485)	(706,720)
Loss on impaiment of investment	(24,432,643)	0	(24,432,643)	(706,720)
Financing Fees	(451,741)	(507,007)	(451,741)	(561,877)
Interest Expense	(360,277)	(170,815)	(2,357,956)	(525,191)
Net Profit / (Loss) Before Income Taxes	(26,033,394)	(2,100,848)	(31,060,206)	(5,225,499)
Income Tax Expense	0	0	0	0
Net Profit / (Loss)	$ (26,033,394)	$ (2,100,848)	$ (31,060,206)	$ (5,225,499)
NET PROFIT / (LOSS) PER COMMON SHARE - BASIC AND DILUTED	$ (0.42)	$ (0.16)	$ (1.22)	$ (0.40)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED	61,473,246	13,200,405	25,414,306	13,074,143
NET PROFIT / (LOSS) PER COMMON SHARE - DILUTED	$ (0.42)	$ (0.16)	$ (1.22)	$ (0.40)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	61,473,246	13,200,405	25,414,306	13,074,143

Consolidated Statements of Cash flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash provided (used) from operating activities
Net Income (Loss)	$ (31,060,206)	$ (4,518,779)
Depreciation	126,129	322,308
Shares issued for inducement	77,043	706,720
Share based expense	95,218	1,027,725
Loss on impairment of investment	21,197,821	0
Finance fees and debt Discount	(706,720)	507,007
Change in accounts receivable	181,868	(26,269)
Change in inventory	1,772,108	265,239
Change in other assets	143,932	0
Change in Accounts Payable and Accrued Expenses	6,530,849	872,514
Change in Accrued Expenses - related party	135,944	249,585
Change in Unearned Revenue	(74,310)	(198,236)
Net cash provided (used) from operating activities	(1,580,324)	(792,186)
Cash used in investing activities
Investment in Infusionz	0	0
Purchase of Equipment	(668,324)	(24,230)
Net cash used in investing activities	668,324	(24,230)
Cash provided by financing activities
Proceeds from Notes Payable	1,012,000	525,000
Payment on notes payable	(100,000)	(235,739)
Proceeds from (payments to) Notes Payable related parties	0	265,000
Net cash provided by financing activities	912,000	554,261
Net Increase (Decrease) In Cash	0	(262,155)
Cash At Beginning of Period	0	270,515
Cash At End of Period	0	8,360
Supplemental Cashflow Information
Interest Paid	0	0
Taxes Paid	$ 0	$ 0

Consolidated Balance Sheet - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 0	$ 0
Accounts receivable - net	344,307	526,175
Inventory	0	1,772,108
Prepaid Expenses	0	28,500
Deposits	2,155	117,587
Total Current Assets	346,462	2,444,370
Property and Equipment - Net	732,250	1,526,703
Loan receivable	50,000	50,000
Right of use asset	480,062	57,327
Goodwill	300,000	21,865,198
Investment Infusionz	0	0
Other assets	23,594	67,290
Total Assets	1,932,368	26,010,888
Current Liabilities:
Accounts payable	3,517,296	2,342,046
Accrued expenses	2,566,857	1,109,336
Accrued Expenses related party	481,332	163,556
Unearned revenue	362,577	436,887
Due to Upexi	1,586,936	504,058
Customer JV account liabilities	300,000	300,000
Lease liability current	358,812	57,327
Notes payable current	531,000	531,000
Notes payable PPP	0	0
Notes payable - related party	91,500	91,500
Notes Payable - Convertibles Related Party	1,909,599	1,773,655
Notes payable - convertibles (net of debt discount)	21,422,142	19,872,470
Total Current Liabilities	33,128,051	27,181,835
Long-Term Debt:
Lease liability	121,250	0
Notes payable	147,807	150,000
Total Liabilities	33,397,108	27,331,835
Stockholders' (Deficit)
Shares to be issued	24,717	3,853,649
Common stock ($0.00001 par value); 950,000,000 shares authorized; 61,473,246 and 14,250,659 shares issued and outstanding at September 30, 2023 and December 31, 2022 respectively	754	284
Additional paid-in capital	11,179,550	6,434,677
Accumulated deficit	(51,169,760)	(20,109,557)
Total Stockholders' (Deficit)	(31,464,739)	(1,320,947)
Total Liabilities and Stockholders' Deficit	1,932,369	26,010,888
Series C Preferred Stock
Stockholders' (Deficit)
Preferred stock, value	0	0
Series A Preferred Stock
Stockholders' (Deficit)
Preferred stock, value	0	0
Series D Preferred Stock [Member]
Stockholders' (Deficit)
Preferred stock, value	8,500,000	8,500,000
Series B Preferred Stock
Stockholders' (Deficit)
Preferred stock, value	$ 0	$ 0